Live
- 39 candidates file papers on Day 1
- ED arrests AAP MLA Amanatullah Khan in Waqf Board appointment scam
- LS polls: Union Minister Bhagwanth Khuba, Dingaleshwara seer, Priyanka Jarkiholi file nominations in K'taka
- Amid show of strength, Congress’ Praniti Shinde files nomination from Solapur
- Tamil Nadu Police gives clean report to Isha Foundation in missing volunteers case
- Home Minister Amit Shah to address public meeting in Goa on April 24
- Gurgaon Open: M Dharma fires 67 for two-shot lead on penultimate day
- Sharad Pawar made many attempts to finish Shiv Sena, claims Maha minister
- Former England opener Raman Subba Row dies aged 92
- IPL 2024: Impact player rule is affecting the progress of half all-rounders, says Zaheer Khan
Natco, Gilead in pact for hepatitis C drug
City-based Natco Pharma on Monday said it inked a non-exclusive licensing agreement with US-based Gilead Sciences to manufacture and sell generic versions of its chronic hepatitis C medicines.
Hyderabad: City-based Natco Pharma on Monday said it inked a non-exclusive licensing agreement with US-based Gilead Sciences to manufacture and sell generic versions of its chronic hepatitis C medicines.
This agreement allows Natco to expand access to these chronic hepatitis C medicines in 91 developing countries, the company in a release.
"Under the license, Natco can set its own price for the generic products it produces, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities," it explained.
The medicines covered by the agreement include sofosbuvir (Sovaldi), ledipasvir/sofosbuvir and the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C.
